PL2545917T3 - Nowy agonista EP4 - Google Patents
Nowy agonista EP4Info
- Publication number
- PL2545917T3 PL2545917T3 PL11753372T PL11753372T PL2545917T3 PL 2545917 T3 PL2545917 T3 PL 2545917T3 PL 11753372 T PL11753372 T PL 11753372T PL 11753372 T PL11753372 T PL 11753372T PL 2545917 T3 PL2545917 T3 PL 2545917T3
- Authority
- PL
- Poland
- Prior art keywords
- agonist
- novel
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010051127 | 2010-03-08 | ||
| JP2010246208 | 2010-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2545917T3 true PL2545917T3 (pl) | 2017-01-31 |
Family
ID=44563514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11753372T PL2545917T3 (pl) | 2010-03-08 | 2011-03-08 | Nowy agonista EP4 |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP2545917B1 (pl) |
| JP (1) | JP5734952B2 (pl) |
| KR (1) | KR101760970B1 (pl) |
| CN (1) | CN102917703B (pl) |
| AU (1) | AU2011225259B2 (pl) |
| BR (1) | BR112012022632B1 (pl) |
| CA (1) | CA2792403C (pl) |
| DK (1) | DK2545917T3 (pl) |
| ES (1) | ES2593229T3 (pl) |
| HU (1) | HUE030206T2 (pl) |
| MX (1) | MX2012010483A (pl) |
| PL (1) | PL2545917T3 (pl) |
| PT (1) | PT2545917T (pl) |
| RU (1) | RU2564414C2 (pl) |
| TW (1) | TWI555744B (pl) |
| WO (1) | WO2011111714A1 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2015DN02814A (pl) * | 2012-10-26 | 2015-09-11 | Asahi Glass Co Ltd | |
| CN107286160A (zh) * | 2017-06-05 | 2017-10-24 | 毛佳婧 | 一种抗肝炎药物的哌啶并吡啶并吡唑‑锌配合物的制备方法 |
| CN111278464A (zh) * | 2017-08-31 | 2020-06-12 | 柏林夏瑞蒂医科大学 | 用于防止妥协性患者中肌肉骨骼损伤愈合不良的免疫调节 |
| JP7233087B2 (ja) * | 2019-03-18 | 2023-03-06 | 公立大学法人横浜市立大学 | 抗動脈硬化剤 |
| HU231350B1 (hu) | 2019-12-18 | 2023-01-28 | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt | Eljárás királis prosztaglandin-enol intermedier előállítására, és az eljárásban hasznos köztitermék vegyületek |
| CN119212700A (zh) | 2022-05-16 | 2024-12-27 | Agc株式会社 | IL-6和/或IL-1β抑制剂 |
| GB202211232D0 (en) | 2022-08-02 | 2022-09-14 | Heptares Therapeutics Ltd | Prostaglandin EP4 receptor agonist compounds |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE788209A (fr) | 1971-09-01 | 1973-02-28 | Pfizer | Derives tetrazoyliques des prostaglandines naturelles |
| NL7401493A (pl) | 1973-02-08 | 1974-08-12 | ||
| KR970002877B1 (ko) * | 1987-07-17 | 1997-03-12 | 더 누트라스웨트 캄파니 | 고성능 감미제 |
| JP3719524B2 (ja) | 1994-03-17 | 2005-11-24 | 旭硝子株式会社 | ジハロゲン化プロスタサイクリン類の製造方法 |
| DE69531110T2 (de) * | 1994-02-17 | 2004-05-19 | Asahi Glass Co., Ltd. | Difluoroprostacycline, Zwischenprodukte zu deren Herstellung und Herstellungsverfahren |
| JP3769738B2 (ja) * | 1994-04-11 | 2006-04-26 | 旭硝子株式会社 | ジフルオロプロスタサイクリン類 |
| JPH08217772A (ja) | 1995-02-13 | 1996-08-27 | Asahi Glass Co Ltd | ジフルオロ置換ビニルエーテル類の製造方法 |
| TW401408B (en) * | 1995-07-21 | 2000-08-11 | Fujisawa Pharmaceutical Co | Heterocyclic compounds having prostaglandin I2 agonism |
| JP3598611B2 (ja) | 1995-10-17 | 2004-12-08 | 旭硝子株式会社 | ジフルオロ化合物の製造方法 |
| WO1997017974A1 (en) * | 1995-11-14 | 1997-05-22 | Toray Industries, Inc. | Ocular depressor |
| TW416953B (en) * | 1996-09-25 | 2001-01-01 | Takeda Chemical Industries Ltd | Tricyclic compounds for eliciting a prostaglandin I2 receptor agonistic effect, their production and use |
| AUPO440696A0 (en) * | 1996-12-30 | 1997-01-23 | Fujisawa Pharmaceutical Co., Ltd. | New use |
| WO1998041209A1 (fr) * | 1997-03-14 | 1998-09-24 | Toray Industries, Inc. | Agents protecteurs de la cellule nerveuse |
| IT1299191B1 (it) * | 1998-06-23 | 2000-02-29 | Sigma Tau Healthscience Spa | Composizione atta a prevenire e trattare l'osteoporosi e le alterazioni legate alla menopausa |
| CN1216050C (zh) | 1998-10-23 | 2005-08-24 | 东丽株式会社 | 5,6,7-三去甲-4,8-内-间亚苯基pgi2衍生物及含有其的医药 |
| EP1339678B1 (en) * | 2000-11-27 | 2007-09-26 | Pfizer Products Inc. | Ep4 receptor selective agonists in the treatment of osteoporosis |
| EP1481976B1 (en) * | 2002-03-05 | 2012-11-07 | Ono Pharmaceutical Co., Ltd. | 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient |
| WO2003103664A1 (en) | 2002-06-06 | 2003-12-18 | Merck Frosst Canada & Co. | 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases |
| EP1988087A1 (en) | 2007-03-28 | 2008-11-05 | Bayer Schering Pharma Aktiengesellschaft | Novel 5-cyano-prostacyclin derivatives and their use as agents for the treatment of autoimmune diseases |
| CA2736039C (en) * | 2008-09-10 | 2016-06-07 | Asahi Glass Co Ltd | Novel prostaglandin i2 derivative |
-
2011
- 2011-03-08 CN CN201180013010.3A patent/CN102917703B/zh active Active
- 2011-03-08 PL PL11753372T patent/PL2545917T3/pl unknown
- 2011-03-08 MX MX2012010483A patent/MX2012010483A/es active IP Right Grant
- 2011-03-08 JP JP2012504482A patent/JP5734952B2/ja active Active
- 2011-03-08 RU RU2012142653/04A patent/RU2564414C2/ru active
- 2011-03-08 AU AU2011225259A patent/AU2011225259B2/en active Active
- 2011-03-08 ES ES11753372.9T patent/ES2593229T3/es active Active
- 2011-03-08 TW TW100107726A patent/TWI555744B/zh active
- 2011-03-08 PT PT117533729T patent/PT2545917T/pt unknown
- 2011-03-08 EP EP11753372.9A patent/EP2545917B1/en active Active
- 2011-03-08 KR KR1020127026092A patent/KR101760970B1/ko active Active
- 2011-03-08 HU HUE11753372A patent/HUE030206T2/en unknown
- 2011-03-08 DK DK11753372.9T patent/DK2545917T3/en active
- 2011-03-08 WO PCT/JP2011/055411 patent/WO2011111714A1/ja not_active Ceased
- 2011-03-08 CA CA2792403A patent/CA2792403C/en active Active
- 2011-03-08 BR BR112012022632-0A patent/BR112012022632B1/pt active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012022632A2 (pt) | 2017-10-03 |
| AU2011225259B2 (en) | 2015-07-23 |
| PT2545917T (pt) | 2016-10-25 |
| EP2545917A1 (en) | 2013-01-16 |
| EP2545917B1 (en) | 2016-08-03 |
| TW201139421A (en) | 2011-11-16 |
| MX2012010483A (es) | 2012-10-09 |
| AU2011225259A1 (en) | 2012-10-11 |
| HUE030206T2 (en) | 2017-04-28 |
| TWI555744B (zh) | 2016-11-01 |
| KR101760970B1 (ko) | 2017-07-24 |
| RU2012142653A (ru) | 2014-04-20 |
| ES2593229T3 (es) | 2016-12-07 |
| DK2545917T3 (en) | 2016-11-14 |
| JP5734952B2 (ja) | 2015-06-17 |
| KR20130018753A (ko) | 2013-02-25 |
| BR112012022632B1 (pt) | 2020-03-31 |
| CN102917703A (zh) | 2013-02-06 |
| EP2545917A4 (en) | 2014-09-10 |
| JPWO2011111714A1 (ja) | 2013-06-27 |
| RU2564414C2 (ru) | 2015-09-27 |
| CA2792403A1 (en) | 2011-09-15 |
| WO2011111714A1 (ja) | 2011-09-15 |
| CA2792403C (en) | 2018-06-12 |
| CN102917703B (zh) | 2015-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP3607A (en) | Substituted imidazopyridazines | |
| GB2498161B (en) | Bollard mounting | |
| SMT201700319T1 (it) | Pirrolidin-2-carbossammidi sostituite | |
| AP2012006640A0 (en) | New aminopyrazoloquinazolines | |
| EP2565190A4 (en) | TETRAHYDROBENZOTHIOPHENE COMPOUND | |
| GB201021830D0 (en) | Handset | |
| GB201016209D0 (en) | Novel device | |
| EP2637960A4 (en) | IMPROVED BLOCK | |
| ZA201304430B (en) | Substituted sodium-1h-pyrazole-5-olate | |
| GB201117661D0 (en) | Early entry | |
| PT2545917T (pt) | Novo agonista de ep4 | |
| GB201301684D0 (en) | Early entry | |
| GB201120098D0 (en) | Early entry | |
| GB2478015B (en) | Cylinder | |
| AU4402P (en) | El Alamein xTriticosecale | |
| GB201003502D0 (en) | Novel inhibitors | |
| GB201003936D0 (en) | Novel inhibitors | |
| GB201006605D0 (en) | Novel inhibitors | |
| GB201006086D0 (en) | Early entry | |
| GB201108547D0 (en) | Early Entry | |
| PH32010000428S1 (en) | Jar | |
| TWM388299U (en) | Jar | |
| GB201018597D0 (en) | Inhibitors | |
| GB201002829D0 (en) | Novel copmounds | |
| GB201017451D0 (en) | Constructional block |